Pacritinib is a Janus kinase 2 (JAK2) inhibitor used primarily to treat myelofibrosis, a type of bone marrow cancer. It works by targeting and inhibiting the JAK2 enzyme, which plays a role in the production of blood cells. By inhibiting this enzyme, pacritinib helps reduce inflammation and abnormal cell production associated with myelofibrosis.
Cleanchem is a trusted provider of premium pharmaceutical reference materials, specializing in Pacritinib and its associated compounds. Our catalog includes pharmacopeial and non-pharmacopeial Pacritinib impurities, metabolites, nitrosamine derivatives (N-NO compounds), and stable isotope-labeled products. These reference standards play a critical role in pharmaceutical R&D, supporting activities such as product formulation, ANDA and DMF submissions, quality assurance, analytical method development, and stability assessments.
All Pacritinib-related substances undergo comprehensive characterization and are delivered with complete Certificates of Analysis and supporting analytical documentation to ensure regulatory adherence. Upon request, we can offer EP/USP traceable standards. Our products are routinely re-evaluated to maintain consistent quality and performance.
English
Arabic
Chinese (Simplified)
French
Japanese
Portuguese
Russian
Spanish
